Year: 2020

Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease

Written by Customer Service on November 11, 2020. Posted in Public Companies.

First Ever Study with take-home capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal AntibodyPotential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s DiseaseCrohn’s Disease Therapeutics Market Size $4.7 Billion by 2025Phase1b/2 clinical study to be conducted in the United States and several European countriesNEW YORK and LONDON, Nov. 11, 2020 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced it is collaborating with Parexel Biotech (“Parexel”), a division of a leading global clinical research organization (“CRO”), Parexel International (IRL) Limited, to conduct a global Phase 1b/2 trial with enteric-coated...

Pinduoduo publishes ESG report to outline progress in managing environmental, social and governance matters

Written by Customer Service on November 11, 2020. Posted in Public Companies.

SHANGHAI, China, Nov. 11, 2020 (GLOBE NEWSWIRE) — Pinduoduo Inc. (“Pinduoduo”)(NASDAQ: PDD) published its first ESG report to outline our progress in managing environmental, social and governance matters. The full ESG report is available on our website https://stories.pinduoduo-global.com/about/corporate-responsibility.Pinduoduo was established in 2015 with the goal of bringing more value-for-money products and more fun to our users. For us, delivering the best value for money is not about squeezing suppliers for the lowest price, but about systematically examining each part of the supply chain to release more value for a win-win situation.Both consumers and merchants have embraced our vision and the company has grown rapidly, hitting many milestones, including:Surpassing 1 trillion yuan in GMV in 2019Reaching almost 700 million...

Enstar Group Limited legt Ergebnisse für das dritte Quartal vor

Written by Customer Service on November 11, 2020. Posted in Public Companies.

Nettogewinne von 615,0 Millionen USD und 896,7 Millionen USD für die drei bzw. neun Monate zum 30. September 2020, vornehmlich aufgrund der guten AnlageperformanceNicht auf GAAP basierende operative Erträge in Höhe von 574,4 Millionen USD und 804,2 Millionen USD für die drei bzw. neun Monate zum 30. September 2020Steigerung des vollständig verwässerten Buchwerts je Aktie um 13,8 % und 22,4 % in den drei bzw. neun Monaten zum 30. September 2020 (nicht annualisiert)HAMILTON, Bermuda, Nov. 11, 2020 (GLOBE NEWSWIRE) — Die Enstar Group Limited (Nasdaq: ESGR) hat heute bei der SEC auf Formular 10-Q ihren Quartalsbericht zur Ertrags- und Finanzlage für die drei bzw. neun Monate zum 30. September 2020 eingereicht.Enstar meldete für die drei und neun Monate zum 30. September 2020 konsolidierte Nettogewinne in Höhe von 615,0 Millionen USD...

Bavarian Nordic Announces Interim Results for the First Nine Months of 2020

Written by Customer Service on November 11, 2020. Posted in Public Companies.

COPENHAGEN, Denmark, November 11, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results for the first nine months of 2020 and business progress for the third quarter of 2020. The Company raises its EBITDA guidance from DKK 675 million to DKK 725 million and upgrades year-end guidance on cash.Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “While during the third quarter of 2020 we successfully continued the transformational initiatives linked to the commercialization of Bavarian Nordic, the global COVID-19 pandemic has unfortunately impacted many parts of our business. The markets for Rabipur/RabAvert and Encepur have been adversely impacted by the measures taken to combat COVID-19 and the decline in the travel segment. In contrast, the sales of JYNNEOS have been...

Bavarian Nordic offentliggør delårsregnskab for de første ni måneder af 2020

Written by Customer Service on November 11, 2020. Posted in Public Companies.

KØBENHAVN, Danmark, 11. november 2020 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag regnskab for de første ni måneder af 2020 samt rapporterede på begivenheder for tredje kvartal 2020. Selskabet løfter EBITDA-forventningerne fra DKK 675 mio. til DKK 725 mio. og opjusterer forventningerne til likvider ved årets udgang.Administrerende direktør i Bavarian Nordic, Paul Chaplin udtaler: “På trods af at vi succesfuldt har fortsat det transformative arbejde med kommercialiseringen af Bavarian Nordic i tredje kvartal 2020, har COVID-19 pandemien desværre påvirket mange områder af vores forretning. Markederne for Rabipur/RabAvert og Encepur er negativt påvirket af de forholdsregler, der er iværksat for at forhindre smittespredning, herunder det afledte fald i rejseaktiviteten. I modsætning er salget af JYNNEOS mere robust og muliggør...

Nine-month interim report (Q3) 2020

Written by Customer Service on November 11, 2020. Posted in Public Companies.

ALK reports 52% tablet growth and 61% earnings growth in Q3 (unaudited)ALK’s revenue returned to growth in Q3 with 7% revenue growth as sales across the tablet portfolio grew 52%, led by Europe and International markets which were resilient to pandemic-related market constraints. This result is achieved despite the continuing negative impact of COVID-19 on its legacy business, predominantly in the USA. ALK’s full-year financial outlook has been updated.Q3 2020 highlightsTotal revenue was up 7% organically in local currencies at DKK 772 million (739). Planned product discontinuations reduced growth by approximately 4 p.p. Currencies reduced reported growth by 2 p.p.Tablet sales grew by 52% to DKK 281 million (185), while combined SCIT and SLIT-drops sales were down 11% on the effects of COVID-19 and planned portfolio rationalisation.Operating...

Nine-month interim report (Q3) 2020

Written by Customer Service on November 11, 2020. Posted in Public Companies.

Bemærk venligst, at rapporten udelukkende findes på engelsk.ALK reports 52% tablet growth and 61% earnings growth in Q3 (unaudited)ALK’s revenue returned to growth in Q3 with 7% revenue growth as sales across the tablet portfolio grew 52%, led by Europe and International markets which were resilient to pandemic-related market constraints. This result is achieved despite the continuing negative impact of COVID-19 on its legacy business, predominantly in the USA. ALK’s full-year financial outlook has been updated.Q3 2020 highlightsTotal revenue was up 7% organically in local currencies at DKK 772 million (739). Planned product discontinuations reduced growth by approximately 4 p.p. Currencies reduced reported growth by 2 p.p.Tablet sales grew by 52% to DKK 281 million (185), while combined SCIT and SLIT-drops sales were down 11% on the...

PCI Biotech third quarter 2020 results

Written by Customer Service on November 11, 2020. Posted in Earnings Releases And Operating Results.

Oslo (Norway), 11 November 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q3 2020 results. Please find enclosed the report and presentation.HighlightsfimaChem*The first patient has been enrolled in the RELEASE study in South Korea, less than three months after opening of the first study site in Asia. All the nine planned study sites in South Korea and Taiwan are now open, with initial good screening activity*Several initiatives are being implemented in the RELEASE study to recoup long-term recruitment projections. Besides going into Asia, the most important initiative is the protocol amendment made to expand the eligible patient population. Full approvals of the protocol amendment are received in 10 European countries, South Korea, Taiwan and US. Seven sites are pending local ethic...

ABN AMRO reports net profit of EUR 301 million in Q3 2020

Written by Customer Service on November 11, 2020. Posted in Earnings Releases And Operating Results.

ABN AMRO reports net profit of EUR 301 million in Q3 2020Net profit at EUR 301 million in Q3 2020, reflecting good operational performance and moderating impairmentsStrong digital backbone and dedication of employees ensures consistent services to our clients during Covid-19Net interest income continues to be impacted by pressure on deposit margins and lower corporate loan volumesOn track to achieve a cost level of around EUR 5.1 billion for 2020, excluding provisions for the CIB reviewCost/income ratio for Q3 was 61.5%, return on equity 5.6%Strong capital position, Basel III CET1 ratio of 17.2% and Basel IV CET1 of around 15%, provides resilienceProgressing on CIB non-core portfolio wind-down; outcome strategy review to be presented on 30 NovemberRobert Swaak, CEO, comments:‘As the Covid-19 health crisis continues to affect us all, the...

ABN AMRO rapporteert nettowinst van EUR 301 miljoen over Q3 2020

Written by Customer Service on November 11, 2020. Posted in Earnings Releases And Operating Results.

ABN AMRO rapporteert nettowinst van EUR 301 miljoen over Q3 2020 Nettowinst van EUR 301 miljoen in Q3 2020 weerspiegelt goed operationeel resultaat en matigende kredietvoorzieningenSterk digitaal netwerk en toewijding van medewerkers verzekert consistente dienstverlening aan onze klanten tijdens Covid-19Netto rentebaten nog altijd negatief beïnvloed door druk op spaarmarges en lager volume zakelijke kredietenOp koers om kostenniveau over 2020 van circa EUR 5,1 miljard te bereiken, exclusief voorzieningen CIB reviewCost/income ratio over Q3 was 61,5%, rendement op eigen vermogen 5,6%Sterke kapitaalpositie, Basel III CET1 ratio van 17,2% en Basel IV CET1 circa 15%, geeft veerkrachtVorderingen bij afbouw van niet-kernactiviteiten van CIB; bekendmaking resultaten strategie-review op 30 novemberRobert Swaak, CEO:‘Terwijl de Covid-19 gezondheidscrisis...

Year: 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals